Alexion acquires Enobia Pharma Alexion Pharmaceuticals, Inc. today announced that the business has finished its previously announced acquisition of 100 percent of the capital stock of Enobia Pharma Corp., an exclusive biopharmaceutical company focused on the advancement of therapies to take care of patients with ultra-rare and life-threatening genetic metabolic disorders. Goldman, Sachs & Co. Acted as economic advisor to Alexion. Ropes and Gray LLP acted as business lead lawyer to Alexion and Cassels Brock & Blackwell LLP acted as Canadian lawyer to Alexion.About 26 % received care exclusively from a psychiatrist, and 15 % received care from a psychologist or social worker exclusively, the findings showed. Overall, primary care companies saw more kids with ADHD than did mental health companies, caring for a good 42 % of kids identified as having the disorder. On the other hand, they saw fewer children with anxiety or various other mood disorders, the researchers found. And nearly three-quarters of ADHD children being treated by a principal care doctor were prescribed medication, weighed against 61 % of those receiving treatment from a psychiatrist, the scholarly study authors said. ‘This finding most likely reflects the fact that the American Academy of Pediatrics provides urged primary treatment pediatricians to take a dynamic role in the treatment of ADHD, and that clinical guidelines for pediatricians recommend that medication should be considered a first-line treatment for all youth with ADHD that are 6 years and older,’ said Dr.